In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Bioheart completes its IPO one year later

Executive Summary

After filing for its initial public offering a year ago, Bioheart (cardiovascular therapeutics) has finally sold 1.1mm common shares at $5.25 apiece netting $4.3mm. At various points throughout the year, it had hoped to sell up to 4.17mm shares at prices of up to $16.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Medical Devices
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register